Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
机构：[1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China[2]Department of Oncology, The First Afliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China[3]Department of Respiration, Shanghai Chest Hospital, Shanghai, China[4]Oncology Chemotherapy Department, The First Afliated Hospital of USTC (Anhui Provincial Hospital), Hefei, China[5]Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Beijing, China [6]Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, China[7]Department of Thoracic Tumor, Hubei Cancer Hospital, Wuhan, China[8]Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China[9]Respiratory and Critical Care Medicine, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China[10]Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China[11]Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Afliated Cancer Hospital of Nanjing Medical University, Nanjing, China[12]Department of Medical Oncology, Zhengzhou Central Hospital, Zhengzhou, China[13]Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China[14]Department of Medical Oncology, The First Afliated Hospital of Henan University of Science and Technology, Luoyang, China[15]Thoracic Medicine Department, Hunan Cancer Hospital and The Afliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China[16]Department of Gastroenterology, The Afliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[17]Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China中国医科大学附属盛京医院中国医科大学盛京医院[18]Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China[19]Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Background The combination of immune checkpoint inhibitors and antiangiogenic agents has been effective in treating multiple cancers. This was further explored in an open-label, multicenter phase 2 basket study (NCT04346381), which evaluated the antitumor activity and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (a receptor tyrosine kinase inhibitor) in patients with advanced solid tumors. We herein report the findings from the cohort of advanced NSCLC patients who progressed after treatment with platinum-doublet chemotherapy and immunotherapy.Methods Eligible patients were enrolled and treated with camrelizumab (200 mg once every 3 weeks via intravenous infusion) and oral famitinib (20 mg once daily). The primary endpoint was the objective response rate (ORR). Secondary endpoints included the disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety.Results Forty patients were enrolled in this cohort, with a median follow-up duration of 11.5 months. Three patients (7.5%) achieved a partial response, and 29 patients (72.5%) achieved stable disease. The ORR and DCR with this combination regimen were 7.5% (95% CI, 1.6-20.4) and 80.0% (95% CI, 64.4-90.9), respectively. The median DoR was 12.1 months (95% CI, 10.3-not reached). The median PFS was 5.4 months (95% CI, 4.1-7.5), and the median OS was 12.1 months (95% CI, 9.1-16.7). The estimated 12-month OS rate was 51.5% (95% CI, 34.9-65.9). The most frequent grade 3 or higher treatment-related adverse events occurring in more than 5% of patients included hypertension (27.5%), palmar-plantar erythrodysesthesia syndrome (10%), decreased neutrophil count (10%), and proteinuria (7.5%).Conclusion Camrelizumab plus famitinib demonstrated favorable benefits in PFS and OS, along with manageable safety profiles, in patients with advanced NSCLC who progressed after platinum-doublet chemotherapy and immunotherapy. This finding warrants further exploration.
基金：
Jiangsu Hengrui Pharmaceuticals Co., Ltd.; Outstanding Discipline Leader Program - Science and Technology Commission of Shanghai Municipality [21XD1423200]; National Key Clinical Program in Thoracic Oncology (2023)
第一作者机构：[1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Ren Shengxiang,Xiong Anwen,Yu Jia,et al.Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study[J].CANCER IMMUNOLOGY IMMUNOTHERAPY.2024,73(7):doi:10.1007/s00262-024-03715-4.
APA：
Ren, Shengxiang,Xiong, Anwen,Yu, Jia,Wang, Xicheng,Han, Baohui...&Zhou, Caicun.(2024).Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.CANCER IMMUNOLOGY IMMUNOTHERAPY,73,(7)
MLA：
Ren, Shengxiang,et al."Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study".CANCER IMMUNOLOGY IMMUNOTHERAPY 73..7(2024)
